Richard Douglas

Richard Douglas

Net worth: 1 M $ as of 31/05/2026

73 year
Health Technology
Consumer Services

Profile

Dr. Richard H.
Douglas
is an Independent Chairman at MaxCyte, Inc., a Chairman at Aldeyra Therapeutics, Inc. and an Independent Director at Novavax, Inc. He is on the Board of Directors at Novavax, Inc., Valneva Usa, Inc. (United States), Helio Vision, Inc. and Labyrinth Choir, Inc. Dr. Douglas was previously employed as a Senior Vice President-Corporate Development by Genzyme Corp.
and a Director-New Product Development by Integrated Genetics, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Berkeley.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
23/04/2026 73,220 ( 0.04% ) 803 223 $ 31/05/2026
13/04/2026 195,000 ( 0.32% ) 341 250 $ 31/05/2026
21/04/2026 230,577 ( 0.22% ) 278 998 $ 31/05/2026

Richard Douglas active positions

CompaniesPositionStart
IOMAI CORPORATION Director/Board Member 01/01/2002
NOVAVAX, INC. Director/Board Member 06/08/2010
ALDEYRA THERAPEUTICS, INC. Chairman -
MAXCYTE, INC. Chairman 03/11/2021
Director/Board Member -
Director/Board Member -

Former positions of Richard Douglas

CompaniesPositionEnd
Corporate Officer/Principal 01/01/2011
Corporate Officer/Principal 01/01/1989
See the detail of Richard Douglas's experience

Training of Richard Douglas

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

88

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

  1. Stock Market
  2. Insiders
  3. Richard Douglas
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!